333 results about "Threonine" patented technology

The invention belongs to the technical field of bioengineering, and relates to a transaminase mutant, a recombinant genetically engineered bacterium and application of the transaminase mutant in catalytic synthesis of (R)-1-Boc-3-aminopiperidine.The transaminase mutant is obtained by conducting single-point or combined mutation on the 131 site and / or the 197 site of an amino acid sequence shown in SEQ ID NO.2; the mutation sites comprise that the 131 phenylalanine is mutated into aspartic acid, threonine or tyrosine, and / or the 197 lysine is mutated into arginine or leucine. Experimental results show that compared with wild type transaminase, the catalytic activity, the thermal stability and the organic solvent tolerance of the obtained mutants, especially single-point mutants MyTA1-F131Y and MyTA1-K197R and a combined mutant MyTA1-F131Y-K197R, are all remarkably improved, and compared with the wild type transaminase, the catalytic activity, the thermal stability and the organic solvent tolerance of the obtained mutants are all remarkably improved. The mutant MyTA1-F131Y-K197R can be used for efficiently catalyzing asymmetric amination of N-Boc-3-piperidone to synthesize (R)-1-Boc-3-aminopiperidine, the conversion rate of the (R)-1-Boc-3-aminopiperidine after the (R)-1-Boc-3-aminopiperidine reacts for 24 hours under the condition that the substrate concentration is 100 g / L can reach 90% or above, and the mutant MyTA1-F131Y-K197R has a good industrial application prospect.

The invention discloses application of copper-amino acid nano enzyme in preparation of anti-inflammatory drugs, and relates to the technical field of biomedical new materials, amino acids comprise glycine, arginine, histidine, threonine, phenylalanine and cysteine; the ratio of the amino acid to the copper ions is 1: (0.5-5), and the synthesis temperature of the copper-cysteine nano enzyme is 25-125 DEG C. The copper-amino acid nano-enzyme library established by the invention has efficient hydroxyl free radical, superoxide free radical and hydrogen peroxide scavenging activity; wherein the copper-cysteine nano-enzyme shows the highest enzymatic activity, and shows low toxicity and good biocompatibility in both the cell level and the animal level; meanwhile, the copper-cysteine nano-enzyme also shows anti-inflammatory activity and anti-oxidative stress activity, can remarkably improve cell inflammation and body inflammation, relieves and treats dextran sodium sulfate induced mouse ulcerative colitis, and can be further applied to preparation of drugs for treating inflammatory bowel diseases.

The invention provides an SNP (Single Nucleotide Polymorphism) marker for targeted identification of systemic lupus erythematosus of children and application of the SNP marker. A new SNP site (RS25671007) is identified in a child systemic lupus erythematosus patient through whole exon sequencing, the site is located at the 734th pair of basic groups of a PABPC3 gene, and mutation from C to T exists at the site, or mutation from threonine to isoleucine exists in coded amino acid. In addition, in-vitro cell model experiments prove that the SNP causes significant up-regulation of the antibody type transformation function, and the SNP can be used as a reference marker for risk stratification or medication guidance of early targeted diagnosis, detection, gene evaluation and the like of systemic lupus erythematosus of children.

The invention relates to the technical field of bioengineering, in particular to a penicillin G acylase mutant, polynucleotide, an expression vector and application. The penicillin G acylase mutant is obtained by carrying out site-directed mutagenesis on a wild type penicillin G acylase gene of parent Escherichia coli, and carrying out site-directed mutagenesis on the wild type penicillin G acylase gene to obtain the penicillin G acylase mutant. Phenylalanine (F) at the 24th site of an alpha chain, proline (P) at the 383rd site of a beta chain, threonine (T) at the 384th site of the beta chain, glutamic acid (G) at the 385th site of the beta chain and serine (S) at the 386th site of the beta chain of the penicillin G acylase are introduced and mutated by a whole plasmid PCR (Polymerase Chain Reaction) technology to obtain mutants. When the penicillin G acylase mutant obtained by the invention is used for catalyzing methyl mandelate and 3-(1-methyl-1H-tetrazole-5-yl) thiomethyl-7-aminocephalosporanic acid to synthesize cefamandole, the synthesis activity is improved, and meanwhile, the side reaction rate is greatly reduced.

The invention relates to a protein consisting of an amino acid sequence in which at least one modification selected from the group consisting of the following [1] to [7] is introduced in the amino acid sequence represented by SEQ ID NO: 1: [1] a modification in which the amino acid residue at a position 103 is substituted with a lysine residue, [2] a modification in which the amino acid residue at a position 76 is substituted with a cysteine residue, [3] a modification in which the amino acid residue at a position 144 is substituted with a cysteine residue, [4] a modification in which the amino acid residue at a position 134 is substituted with a glycine residue, [5] a modification in which the amino acid residue at a position 222 is substituted with a methionine residue, [6] a modification in which the amino acid residue at a position 73 is substituted with a glutamine residue, and [7] a modification in which the amino acid residue at a position 203 is substituted with a threonine residue.

The application relates to the technical field of beef cattle breeding, and particularly discloses a compound preparation for promoting the feed intake, daily weight gain and improving the meat quality of beef cattle and application thereof, which is prepared from the following components in percentage by volume: 40% of micro-ecological preparation, 30% of hawthorn, 10% of medicated leaven, 10% of malt, 5% of areca nut and 5% of dried tangerine or orange peel; the compound preparation is prepared from microorganisms and multiple natural Chinese herbal medicines in a specific and scientific matching ratio; experiments prove that the compound preparation can increase the feed intake of beef cattle by 11.33%, increase the daily weight gain by 16.16%, and significantly shorten the breeding cycle; meanwhile, the contents of aspartic acid, threonine, glutamic acid, alanine, valine, isoleucine, leucine, tyrosine, phenylalanine, lysine, arginine and proline in the muscle are significantly increased, the nutritional quality and flavor taste of beef are effectively improved, the preparation is natural, residue-free and side-effect-free, the preparation method is simple, the cost is low, and the preparation has extremely high practical value and popularization prospect.

The invention discloses laying hen feed immune peptide and a preparation method thereof, and belongs to the technical field of laying hen feed additives. The immune peptide is prepared from the following raw materials in percentage by mass: 29% of threonine, 25% of chili meal, 20% of Chinese prickly ash seeds and 26% of Chinese prickly ash leaf powder. The preparation method comprises the following steps: respectively crushing the raw materials until the particle size is 0.3-0.8 mm, mixing the zanthoxylum bungeanum seed powder, the pepper meal powder and the zanthoxylum bungeanum leaf powder in sequence, and then adding the threonine powder, and mixing for 25-30 minutes to obtain a finished product. The feed has the core advantages that by utilizing the synergistic effect of natural active ingredients in the threonine, the pepper meal, the Chinese prickly ash seeds and the Chinese prickly ash leaf powder, the immune function of laying hens is remarkably enhanced, the morbidity is reduced, meanwhile, the laying rate of the laying hens, the eggshell quality and the egg nutritional value are improved, and the raw materials are natural, free of residues and high in safety.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

The invention discloses application of a TREX1 protein non-substrate DNA binding interface as a target spot in preparation of an immunoregulation medicine, and relates to the technical field of biological medicines. Wherein the TREX1 protein is a human source TREX1 protein, and the non-substrate DNA binding interface comprises threonine at the 49th site of the TREX1 protein, arginine at the 211th site of the TREX1 protein, glutamine at the 213th site of the TREX1 protein and arginine at the 217th site of the TREX1 protein. The non-substrate DNA binding interface in the TREX1 is found for the first time, the key function of the non-substrate DNA binding interface in maintaining immune homeostasis and tumor immune escape is defined through mutation verification and functional analysis, and a new anti-tumor immune strategy with the non-substrate DNA binding interface as a target spot is provided. The discovery not only makes up the blank of TREX1 structure research, but also provides a new theoretical basis and a drug development direction for immune regulation molecule design.

The present disclosure can improve the degree of soy protein proteolysis and the ability to produce valine, isoleucine, and leucine, which are branched-chain amino acids, as well as other amino acids, such as threonine, glycine, tyrosine, and lysine. Accordingly, the present disclosure can prevent sarcopenia and has antioxidant activity. Also, the present disclosure can maintain protein metabolic balance and relieve sarcopenia by muscle synthesis.The self-aggregation, hydrophobicity, and intestinal adhesion of a mixed strain is improved compared to a case where a single strain used for the mixed strain is used. Therefore, when the mixed strain of the present disclosure is ingested, the strain can remain for a long time in the intestine.

To provide a human interferon-beta mutant having a double mutation and a method for improving the safety of the human interferon-beta mutant.SOLUTION: Provided are a human interferon-beta variant comprising an amino acid sequence in which the 17th amino acid cysteine of human interferon-beta is substituted with serine and the 27th amino acid arginine is substituted with threonine, and a method for improving the stability of a human interferon-beta R27T variant, the method comprising the step of changing the 17th amino acid cysteine of a human interferon-beta R27T variant, in which the 27th amino acid arginine of human interferon-beta is substituted with threonine, to serine.SELECTED DRAWING: Figure 1

To provide an improved antibody-drug conjugate and a pharmaceutical composition containing the antibody-drug conjugate.SOLUTION: The invention is based on the concept that it is possible to generate antibodies that exhibit improved potency (e.g., one or more of increased (e.g., detectable increase) toxin release in target mammalian cells, increased (e.g., detectable increase) killing of target mammalian cells, and increased (e.g., detectable increase) endolysosomal delivery). In some embodiments of any of the antibodies described herein, the heavy chain CH1 - CH2 - CH3 sequence consisting of the specific sequence comprises a substitution of lysine to cysteine at amino acid position 105 and a deletion of threonine at amino acid positions 106 and 108.SELECTED DRAWING: None

This invention discloses a hair repair composition for permed hair, comprising, by weight: 0.02-1.0 parts hydrolyzed plant protein, 0.1-2.0 parts biomimetic amino acid complex, 50-95 parts carrier, and 0.5-15 parts additives. The hydrolyzed plant protein is obtained from Moringa seed protein through multi-enzyme synergistic hydrolysis, with a molecular weight less than 3500 Daltons. The biomimetic amino acid complex includes at least wheat amino acids, soybean amino acids, arginine hydrochloride, serine, and threonine. Under weakly acidic conditions, this composition can simultaneously repair broken disulfide bonds, hydrogen bonds, and ionic bonds in hair. The hydrolyzed plant protein provides disulfide bond reconnection sites, and the biomimetic amino acid complex constructs a multi-point weak bond network through hydroxyl and ionic groups, achieving "triple bond repair" synergistically. This invention can significantly improve the mechanical strength, elasticity, and breakage resistance of damaged hair, with long-lasting, gentle, and safe repair effects, suitable for daily care of damaged hair after perming and dyeing.

This invention relates to the field of genetic engineering technology, specifically to a mutant NAD(P)H-quinone dehydrogenase, engineered microorganisms, and their applications. The mutant NAD(P)H-quinone dehydrogenase provided by this invention can effectively enhance the threonine production capacity of bacterial strains. Introducing this mutant NAD(P)H-quinone dehydrogenase into bacterial strains significantly improves the threonine yield and conversion rate. This mutant NAD(P)H-quinone dehydrogenase provides a new strategy and method for improving the performance of amino acid-producing strains such as threonine, and has promising application prospects in amino acid strain modification.

The invention relates to a tetrapeptide of formula N-Palmitoyl-Lys-Thr-Phe-Lys, for use in the prevention and / or treatment of human atopic dermatitis (AD), as well as to a composition comprising at least said tetrapeptide and at least one physiologically acceptable excipient, for use in the prevention and / or treatment of human atopic dermatitis (AD).

The invention relates to a chemoenzymatic synthesis method of a high-glucose-type homogeneity mucoprotein core structural domain. The method comprises the following steps: firstly, catalytically synthesizing a key alpha-linked glycosylated amino acid block Fmoc-GalNacalpha-Ser / Thr-OH at a low temperature (-20 DEG C to 0 DEG C); then assembling the building blocks on a repeated polypeptide skeleton rich in proline, serine and threonine at accurate intervals (3-5 amino acid residues) through a solid-phase peptide synthesis technology to form a'sugar chain growth scaffold '; then, a series of high-specificity glycosyl transferases are used for carrying out sequential and directional sugar chain enzymatic extension on the scaffold, and a uniform core structure (such as a core type 3) is constructed; and finally, performing high-efficiency purification by a three-step series method of size exclusion chromatography, ion exchange chromatography and lectin affinity chromatography. The technical bottleneck of inhomogeneity (lt, 70%) of glycoforms in a traditional method is overcome, the mucoprotein core fragment with glycoform homogeneity larger than or equal to 95% and bioactivity highly similar to that of natural mucoprotein can be prepared on a large scale, and the method has wide application prospects in the biomedical fields of mucous membrane protective agents, drug delivery carriers and the like.

This disclosure relates to methods of treating cancer comprising administering an effective amount of a platinum-based chemotherapy agent in combination with a microtubule associated serine / threonine-protein kinase (MAST) inhibitor and / or a glucocorticoid receptor binding agent and / or a hsp90 binding agent and / or other chemotherapy agents disclosed herein to a subject in need thereof. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising combinations of agents disclosed herein and a pharmaceutically acceptable excipient.

The present disclosure provides a novel solid crystalline form of isopropyl ((11S,12S,13S,9S,12S)-9-amino-12-((1-(6-aminohexyl)-5-fluoro-1H-indol-3-yl)methyl)-4,10,13-trioxo-2-oxa-5,11-diaza-1(3,1)-pyrrolidina-7(1,3)-benzenacyclotridecaphane-12-carbonyl)-L-threoninate (Compound 1), or pharmaceutically acceptable salt thereof, compositions comprising Compound 1 (Form 1A and / or Form 2) synthesis thereof, and an improved crystallization process using Form 2 to prepare Form 1. Novel compositions also include Compound 1 solid Form 1, Form 2 and / or other crystalline and amorphous solid forms of Compound 1.

The invention relates to a PPP2CB phosphatase target small molecule compound and application thereof, and belongs to the field of biological medicine. The invention provides a small molecule compound C16H16N4O, which is specifically combined with a PPP2CB catalytic subunit, and by enhancing the activity of PPP2CB phosphatase, the serine / threonine phosphorylation level of ERK, MAPK, JAK and other kinases in macrophages is remarkably reduced, and the activation of NF-kappa B, JAK-STAT and MAPK-ERK inflammation signal pathways is blocked. The compound is suitable for treating inflammatory storm caused by SARS-CoV-2, influenza virus and staphylococcus aureus infection. In an SARS-CoV-2 infection model, the survival rate of the mice is increased from 0 to 50%; the lung pathological injury is relieved after influenza virus infection. Sepsis caused by staphylococcus aureus USA300 is effectively inhibited, and the death rate is reduced. The clinical transformation potential is realized.

The present application relates to the technical field of genetic engineering, in particular to a transcriptional regulator mutant and application thereof in constructing amino acid production bacteria. The transcriptional regulator mutant provided by the present application can significantly improve the production capacity of bacteria for threonine and other amino acids, and has a good application prospect in the modification of amino acid strains. Based on the mutant, the threonine yield and conversion rate of the recombinant bacteria constructed by the present application are significantly improved, thereby providing a new method and strategy for the modification of threonine and other amino acid strains.

Provided is a cyclic peptide, which has a sequence of cyclo(X1X2X3X4X5X6), wherein X1 is asparagine; X2 is glycine or sarcosine; X3 is arginine; X4 is selected from a group consisting of threonine, tyrosine, and phenylalanine; X5 is lysine; and X6 is selected from a group consisting of tyrosine, valine, and glutamic acid. Provided is a preparation method for the cyclic peptide. Provided is a complex, comprising the cyclic peptide, a linker, and a chelating agent. Provided is a use of the complex as a radionuclide-labeled targeting molecule. Provided is a radionuclide labeling method, comprising bringing a complex that chelates a radionuclide into contact with an object to be labeled by the radionuclide.

The invention discloses a stable GE11m peptide modified extracellular vesicle anti-cancer targeting nano delivery system, a preparation method and application thereof, and belongs to the technical field of biological medicine preparations, the nano delivery system comprises extracellular vesicles which can be genetically engineered by TRAIL and are derived from mammalian cells, and a stable GE11m peptide modified extracellular vesicle anti-cancer targeting nano delivery system and a stable GE11m peptide modified extracellular vesicle anti-cancer targeting nano delivery system, according to the present invention, the surface is connected with the D-type amino acid modified GE11m targeting peptide through the CP05 anchoring peptide, the amino acid sequence of the GE11m targeting peptide is YDHWYDGYTDPQNVI, and the first tyrosine, the fourth tyrosine and the seventh threonine in the GE11m peptide sequence are replaced with the D-type amino acid so as to significantly enhance the protease resistance and the serum stability of the targeting peptide.

The invention discloses a double-function (p) ppGpp synthetase or hydrolase mutant, a biological material and application of the double-function (p) ppGpp synthetase or hydrolase mutant to preparation of L-threonine, and belongs to the technical field of gene engineering. The technical problem to be solved by the invention is how to improve the yield of L-threonine. Relative to a wild type, the bifunctional (p) ppGpp synthetase or hydrolase mutant comprises one or more of the following mutations: K1) mutation of 174th amino acid of SEQ ID NO: 2 into cysteine, K2) mutation of 529th amino acid of SEQ ID NO: 2 into phenylalanine, and K3) insertion of histidine and aspartic acid between 84th amino acid and 85th amino acid of SEQ ID NO: 2. The bifunctional (p) ppGpp synthetase or hydrolase mutant provided by the invention can be used for improving the yield of L-threonine of Escherichia coli.

The invention relates to the technical field of enzyme engineering, in particular to a malic enzyme mutant and application thereof. Specifically, the malic enzyme derived from Escherichia coli is subjected to site mutation screening, and results show that after methionine at the 144th site is mutated into isoleucine (M144I), glutamine at the 253rd site is mutated into isoleucine (Q253I), and threonine at the 327th site is mutated into phenylalanine (T327F), the catalytic efficiency and the catalytic activity are obviously improved, which is of great significance to industrial application.

The invention discloses a generalized pustular psoriasis diagnosis marker based on metabonomics and application of the generalized pustular psoriasis diagnosis marker. The diagnostic marker is prepared from one or more of the following 35 compounds: pyruvic acid, alpha-ketoisovaleric acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, methane thiophosphoric acid, proline, uracil, tranexamic acid, 4-aminobutyric acid, threonine, scopoletin, dodecanol, N-methyl-L-leucine, L-cysteine-glycine and L-kynurenine. The feed additive is prepared from the following raw materials: 3-hydroxybenzoic acid, allantoin, delta-tocopherol, xylofuranose, glucose-1-phosphoric acid, pyrophosphate, taurine, L-asparagine, phthalic acid, 4-(dimethylamino) azobenzene, 5-tert-butyl-1h-indole-2, 3-dione, quinic acid, glucose, histidine, lysine, palmitic acid, 7-methylguanine, oleic acid and whale acid. The marker can be used for accurately distinguishing patients with generalized pustular psoriasis from healthy people.

This invention relates to the field of bioengineering technology, specifically to a cis-epoxysuccinate hydrolase mutant and its applications. The cis-epoxysuccinate hydrolase mutant is obtained by single-point or multi-point mutations at positions 127 and 141 of the amino acid sequence of the wild-type cis-epoxysuccinate hydrolase shown in SEQ ID NO. 1. The single-point mutation involves replacing valine at position 127 with isoleucine, or replacing aspartic acid at position 141 with threonine. The cis-epoxysuccinate hydrolase mutant obtained by this invention exhibits high thermal stability, significantly improving the service life of the cis-epoxysuccinate hydrolase in the industrial production of D(-)-tartaric acid.

The invention belongs to the technical field of biological medicine and molecular biology, and provides a hypertrophic cardiomyopathy virulence gene MYH7c.794Cgt; the invention relates to T (p.Thr265Ile) and an application thereof. The MYH7 gene mutation is located on the ninth exon, the 794th base is mutated from C to T, namely ACC is mutated to ATC, and the 265th amino acid in the coded amino acid sequence is mutated from threonine to isoleucine. The mutation induces cardiac hypertrophy by disrupting energy metabolism-this defect occurs prior to the occurrence of systolic dysfunction. Along with increasingly prominent status of precision medicine in cardiovascular treatment, a treatment strategy aiming at an upstream pathological process (such as energy homeostasis and mitochondrial dysfunction) provides a way with a wide prospect for preventing and treating MYH7-related hypertrophic cardiomyopathy. MYH7 gene screening has important values in the aspects of promoting early diagnosis, guiding timely treatment intervention and realizing risk-based prevention and management.

The invention discloses an anti-cancer oligopeptide designed based on threonine and analogues thereof and application of the anti-cancer oligopeptide, the anti-cancer oligopeptide is obtained by taking KLLKKLLKKLLKKKLLKW as a structural basis, replacing amino acids at different sites with hydroxyl-containing threonine or analogues thereof, and then amidating a C terminal; the structural general formula of the compound is as follows: KXmLKKLLKKLLKW-NH2, wherein X = T, pT, F, Y or pY, and p represents phosphorylation; and m is 2, 3, 6, 7, 10, 11 or 13. The anti-cancer oligopeptide has the advantages of high efficiency, low toxicity, short sequence and the like. In-vitro anti-tumor activity and toxicity experiment results show that the compound has a relatively strong killing effect on various tumor cells, and is low in hemolytic toxicity and high in therapeutic index. Serum stability experiments further show that the protein has relatively high enzymolysis stability. A scanning electron microscope experiment shows that the anti-cancer oligopeptide can quickly kill tumor cells through an effective membrane rupture mechanism. Therefore, the compound has a good application prospect in the aspects of research on novel high-efficiency low-toxicity polypeptide anti-cancer drugs, resistance to multidrug resistance and preparation of anti-cancer drugs.

The application discloses application of Fagopyrum cymosum root powder in preparation of products for improving egg quality or intestinal health of laying ducks, and belongs to the technical field of feed additives. The application provides application of Fagopyrum cymosum root powder in preparation of products for improving egg quality or intestinal health of laying ducks, and the Fagopyrum cymosum root powder can improve eggshell strength, yolk color and eggshell proportion, improve the content of aspartic acid, threonine, glutamic acid, glycine, cystine and leucine in yolk, improve the content of arachidonic acid and arachidonic acid in yolk, and reduce the content of saturated fatty acid in yolk; the Fagopyrum cymosum root powder can improve the activity of maltase in the mucous membrane of the jejunum of laying ducks, and can improve the diversity and abundance of intestinal flora of laying ducks. The application provides a new strategy for improving egg quality or intestinal health of laying ducks.

The present invention relates to the field of polypeptide compositions, and specifically relates to a polypeptide metal chelate and the use thereof in the field of cosmetics. The polypeptide metal chelate is formed by means of the chelation of a polypeptide compound with a metal ion compound. A structure of the polypeptide compound is: [γ-Glu]n-AA, wherein n≥1, and AA is selected from glycine, alanine, valine, leucine, isoleucine, methionine (Met), proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine or histidine. The polypeptide zinc chelate prepared by the present invention has significant oil-controlling and anti-inflammatory effects, and can be compounded with other raw materials to prepare cosmetics with oil control and acne removal effects.